版本:
中国

BRIEF-Takeda, Seattle Genetics announce Lancet publication

June 7 Takeda Pharmaceutical Co Ltd:

* Takeda and Seattle Genetics announce Lancet publication of phase 3 alcanza clinical trial data of adcetris (brentuximab vedotin) for CD30-positive cutaneous t-cell lymphoma

* Takeda - ‍takeda plans to begin to submit data from alcanza trial to regulatory agencies in its territories in 2017​

* Takeda - ‍Seattle Genetics plans to submit these data as part of a supplemental biologics license application to FDA in mid-2017​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐